Phase III regenerative medicine trial for heart failure cleared to start
This article was originally published in Clinica
Executive Summary
A Phase III trial of a regenerative medicine for heart failure, highlighted in Clinica recently, has been cleared to start by Belgian regulators. Cardio3 BioSciences' Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European trial for C3BS-CQR-1, an autologous stem cell therapy for heart failure, which the firm gave details of in August, can now begin (www.clinica.co.uk, 20 August 2012).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.